Drug, meal and formulation interactions influencing drug absorption after oral administration - Clinical implications

被引:362
作者
Fleisher, D
Li, C
Zhou, Y
Pao, LH
Karim, A
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Natl Def Med Ctr, Taipei, Taiwan
[3] GD Searle & Co, Skokie, IL 60077 USA
关键词
D O I
10.2165/00003088-199936030-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-drug, drug-formulation and drug-meal interactions are of clinical concern for orally administered drugs that possess a narrow therapeutic index. This review presents the current status of information regarding interactions which may influence the gastrointestinal (GI) absorption of orally administered drugs. Absorption interactions have been classified on the basis of rate-limiting processes. These processes are put in the context of drug and formulation physicochemical properties and oral input influences on variable GI physiology. Interaction categorisation makes use of a biopharmaceutical classification system based on drug aqueous solubility and membrane permeability and their contributions towards absorption variability. Overlaying this classification it is important to be aware of the effect that the magnitudes of drug dosage and volume of fluid administration can have on interactions involving a solubility rate limits. GI regional differences in membrane permeability are fundamental to the rational development of extended release dosage forms as well as to predicting interaction effects on absorption from immediate release dosage forms. The effect of meals on the regional-dependent intestinal elimination of drugs and their involvement in drug absorption interactions is also discussed. Although the clinical significance of such interactions is certainly dependent on the narrowness of the drug therapeutic index, clinical aspects of absorption delays and therapeutic failures resulting from various interactions are also important.
引用
收藏
页码:233 / 254
页数:22
相关论文
共 189 条
[1]   Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (05) :415-419
[2]   Systemic antifungal agents - Drug interactions of clinical significance [J].
Albengres, E ;
Le Louet, H ;
Tillement, JP .
DRUG SAFETY, 1998, 18 (02) :83-97
[3]   INFLUENCE OF KAOLIN-PECTIN SUSPENSION ON DIGOXIN BIOAVAILABILITY [J].
ALBERT, KS ;
AYRES, JW ;
DISANTO, AR ;
WEIDLER, DJ ;
SAKMAR, E ;
HALLMARK, MR ;
STOLL, RG ;
DESANTE, KA ;
WAGNER, JG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (11) :1582-1586
[4]   PHARMACOKINETIC EVALUATION OF A DRUG INTERACTION BETWEEN KAOLIN-PECTIN AND CLINDAMYCIN [J].
ALBERT, KS ;
DESANTE, KA ;
WELCH, RD ;
DISANTO, AR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (11) :1579-1582
[5]   EFFECT OF MAGNESIUM-ALUMINUM HYDROXIDE AND KAOLIN-PECTIN ON ABSORPTION OF DIGOXIN FROM TABLETS AND CAPSULES [J].
ALLEN, MD ;
GREENBLATT, DJ ;
HARMATZ, JS ;
SMITH, TW .
JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (01) :26-30
[6]   Drug interactions with grapefruit juice [J].
Ameer, B ;
Weintraub, RA .
CLINICAL PHARMACOKINETICS, 1997, 33 (02) :103-121
[7]   ESTIMATING HUMAN ORAL FRACTION DOSE ABSORBED - A CORRELATION USING RAT INTESTINAL-MEMBRANE PERMEABILITY FOR PASSIVE AND CARRIER-MEDIATED COMPOUNDS [J].
AMIDON, GL ;
SINKO, PJ ;
FLEISHER, D .
PHARMACEUTICAL RESEARCH, 1988, 5 (10) :651-654
[8]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[9]  
Bagchi D, 1998, J APPL TOXICOL, V18, P3
[10]  
BECHTOL LD, 1979, CURR THER RES CLIN E, V25, P618